SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
ELV reported Third Quarter 2026 results. The stock moved -1.4% on the print.
ELVearnings

Earnings reactions, page 14

Elevance Health, Inc. (ELV) Q3 FY2026 earnings

October 21, 2026 · SharpeIQ Research Desk

Reported results

  • Operating revenue was $50.4 billion in 3Q 2026, up 0.7% from 3Q 2025.
  • 3Q 2026 diluted EPS was $6.27 and adjusted diluted EPS was $6.99.
  • The benefit expense ratio was 90.6 percent in the third quarter of 2026, an improvement of 70 basis points from the prior year quarter.
  • The operating expense ratio was 11.4 percent and the adjusted operating expense ratio was 11.3 percent in 3Q 2026.
  • Operating cash flow was $1.3 billion for the third quarter of 2026, up $0.1 billion relative to the prior year quarter.

Guidance

  • FY 2026 diluted EPS guidance is at least $22.00.
  • FY 2026 adjusted diluted EPS guidance is at least $29.00.
  • FY 2026 operating cash flow guidance is at least $6.5 billion.

Notes

Results for the nine months ended September 30, 2026 include an accrual of $935 million ($4.28 per share) representing the current best estimate of identified potential exposure for certain historical Medicare Advantage risk adjustment data related to a CMS notice dated February 27, 2026.

Price and volatility reaction

The stock moved -1.4% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -8.4 vol points across the event (constant-maturity series — not the front-week crush).

MeasureValueBasis
Close before release440.182026-10-20
Close after release434.132026-10-21
Realised move-1.4%close to close
30d ATM IV change-8.4 vol ptsconstant-maturity series, not the front expiry
Price and volatility reaction. Closes either side of the release. No front-expiry chain on file for a straddle expected move. SharpeIQ — listed option chain and price_history

Source

The figures above come from the earnings release the company filed with the SEC on 2026-10-21 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →